193 related articles for article (PubMed ID: 25070294)
1. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
2. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Kicinski M; Valpione S; Gandini S; Suciu S; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Robert C; Eggermont AMM; Lorigan P; Mandala M
Eur J Cancer; 2023 Aug; 189():112900. PubMed ID: 37277264
[TBL] [Abstract][Full Text] [Related]
4. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
Johansson CC; Egyházi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Cancer Immunol Immunother; 2009 Jul; 58(7):1085-94. PubMed ID: 19039588
[TBL] [Abstract][Full Text] [Related]
6. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
7. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
Bucheit AD; Chen G; Siroy A; Tetzlaff M; Broaddus R; Milton D; Fox P; Bassett R; Hwu P; Gershenwald JE; Lazar AJ; Davies MA
Clin Cancer Res; 2014 Nov; 20(21):5527-36. PubMed ID: 25165098
[TBL] [Abstract][Full Text] [Related]
8. Improving melanoma classification by integrating genetic and morphologic features.
Viros A; Fridlyand J; Bauer J; Lasithiotakis K; Garbe C; Pinkel D; Bastian BC
PLoS Med; 2008 Jun; 5(6):e120. PubMed ID: 18532874
[TBL] [Abstract][Full Text] [Related]
9. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract][Full Text] [Related]
10. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
12. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Panka DJ; Buchbinder E; Giobbie-Hurder A; Schalck AP; Montaser-Kouhsari L; Sepehr A; Lawrence DP; McDermott DF; Cohen R; Carlson A; Wargo JA; Merritt R; Seery VJ; Hodi FS; Gunturi A; Fredrick D; Atkins MB; Iafrate AJ; Flaherty KT; Mier JW; Sullivan RJ
Mol Cancer Ther; 2014 Dec; 13(12):3210-8. PubMed ID: 25319388
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
[TBL] [Abstract][Full Text] [Related]
14. BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
Braud A; Auloge P; Meyer N; Bouvrais C; Gharbi M; Lang H; Gangi A; Lipsker D
Cardiovasc Intervent Radiol; 2024 May; 47(5):567-572. PubMed ID: 38570342
[TBL] [Abstract][Full Text] [Related]
16. Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
Fitzgerald S; Blenkiron C; Stephens R; Mathy JA; Somers-Edgar T; Rolfe G; Martin R; Jackson C; Eccles M; Robb T; Rodger E; Lawrence B; Guilford P; Lasham A; Print CG
Mol Diagn Ther; 2023 Jul; 27(4):537-550. PubMed ID: 37099071
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of immune markers and BRAF status in melanoma patients: Implications for prognosis.
Kodali N; Alomary S; Lin M; Sikder S; Bhattaru A; Desai SD; Lipner SR
Exp Dermatol; 2024 May; 33(5):e15105. PubMed ID: 38794818
[No Abstract] [Full Text] [Related]
18. Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era.
Hagopian G; Jiang X; Grant C; Brazel D; Kumar P; Yamamoto M; Jakowatz J; Chow W; Tran T; Shen W; Moyers J
ESMO Open; 2024 Feb; 9(2):102193. PubMed ID: 38271786
[TBL] [Abstract][Full Text] [Related]
19. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC; Luke JJ
Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma.
De Falco V; Napolitano S; Esposito D; Guerrera LP; Ciardiello D; Formisano L; Troiani T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
